On Air Now

Listen

Listen Live Now » 101.1 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
74° Feels Like: 74°
Wind: E 7 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Cloudy 65°

Tomorrow

AM Clouds/PM Sun 79°

Sun Night

Mostly Cloudy 66°

Bayer's regorafenib gets priority review by FDA

FRANKFURT (Reuters) - U.S. health regulators granted a priority review for Bayer's cancer drug regorafenib for the treatment of gastrointestinal stromal tumors, potentially speeding up the treatment's route to market.

The U.S. Food and Drug Administration grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies.

A priority review takes six months rather than the usual 10 to 12-months.

Onyx Pharmaceuticals is the U.S. marketing partner for regorafenib, which will be branded as Stivarga.

(Reporting by Ludwig Burger)

Comments